MX2018002901A - Proceso para preparar una vacuna tetravalente atenuada contra el dengue. - Google Patents

Proceso para preparar una vacuna tetravalente atenuada contra el dengue.

Info

Publication number
MX2018002901A
MX2018002901A MX2018002901A MX2018002901A MX2018002901A MX 2018002901 A MX2018002901 A MX 2018002901A MX 2018002901 A MX2018002901 A MX 2018002901A MX 2018002901 A MX2018002901 A MX 2018002901A MX 2018002901 A MX2018002901 A MX 2018002901A
Authority
MX
Mexico
Prior art keywords
preparing
dengue vaccine
tetravalent dengue
attenuated tetravalent
attenuated
Prior art date
Application number
MX2018002901A
Other languages
English (en)
Inventor
Maria Frazatti Gallina Neuza
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of MX2018002901A publication Critical patent/MX2018002901A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un proceso para preparar una vacuna tetravalente atenuada contra el virus del dengue y producto del mismo. La presente invención también se refiere a un proceso de preparación de una vacuna tetravalente contra el dengue para su administración a un sujeto, a un método para inducir una respuesta inmune contra los serotipos 1, 2, 3 y 4 del virus del dengue en un paciente y a un conjunto de elementos de una vacuna tetravalente contra el dengue.
MX2018002901A 2015-09-08 2016-09-06 Proceso para preparar una vacuna tetravalente atenuada contra el dengue. MX2018002901A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/847,422 US10004795B2 (en) 2015-09-08 2015-09-08 Process for preparing an attenuated tetravalent dengue vaccine
PCT/BR2016/050224 WO2017041156A1 (en) 2015-09-08 2016-09-06 Process for preparing an attenuated tetravalent dengue vaccine

Publications (1)

Publication Number Publication Date
MX2018002901A true MX2018002901A (es) 2018-09-18

Family

ID=56268413

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002901A MX2018002901A (es) 2015-09-08 2016-09-06 Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
MX2021013109A MX2021013109A (es) 2015-09-08 2018-03-07 Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013109A MX2021013109A (es) 2015-09-08 2018-03-07 Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.

Country Status (17)

Country Link
US (2) US10004795B2 (es)
EP (1) EP3347043A1 (es)
JP (1) JP6968070B2 (es)
CN (1) CN108289945B (es)
AR (1) AR105966A1 (es)
AU (1) AU2016318349B2 (es)
BR (1) BR102015030332B1 (es)
CL (1) CL2018000609A1 (es)
CO (1) CO2018003451A2 (es)
CR (1) CR20180202A (es)
CU (1) CU24579B1 (es)
EC (1) ECSP18026090A (es)
HK (1) HK1258584A1 (es)
MX (2) MX2018002901A (es)
PE (1) PE20181135A1 (es)
TW (1) TWI733694B (es)
WO (1) WO2017041156A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539565T3 (pl) 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
CA3079151A1 (en) * 2017-10-16 2019-04-25 Serum Institute Of India Private Limited Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
MX2021002586A (es) 2018-09-05 2021-06-08 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta.
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483653C (en) * 2002-05-03 2014-10-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20090246868A1 (en) * 2003-12-19 2009-10-01 Wyeth Serum-free vero cell banking process
WO2006066332A1 (en) * 2004-12-23 2006-06-29 Murray Goulburn Co-Operative Co Limited Method of manufacture of a modified milk powder suitable as a rennet casein extender or replacer
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
PL3539565T3 (pl) * 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine

Also Published As

Publication number Publication date
US10004795B2 (en) 2018-06-26
CU20180025A7 (es) 2018-11-06
PE20181135A1 (es) 2018-07-17
US20170065701A1 (en) 2017-03-09
ECSP18026090A (es) 2018-10-31
CL2018000609A1 (es) 2018-08-17
BR102015030332B1 (pt) 2019-11-05
US20180256702A1 (en) 2018-09-13
EP3347043A1 (en) 2018-07-18
WO2017041156A1 (en) 2017-03-16
MX2021013109A (es) 2021-11-17
US10201600B2 (en) 2019-02-12
JP6968070B2 (ja) 2021-11-17
CR20180202A (es) 2018-08-10
AU2016318349A1 (en) 2018-04-19
CN108289945B (zh) 2022-05-31
CU24579B1 (es) 2022-02-04
AR105966A1 (es) 2017-11-29
BR102015030332A2 (pt) 2016-07-05
TWI733694B (zh) 2021-07-21
CO2018003451A2 (es) 2018-11-30
HK1258584A1 (zh) 2019-11-15
TW201718008A (zh) 2017-06-01
CN108289945A (zh) 2018-07-17
AU2016318349B2 (en) 2019-10-17
JP2018527408A (ja) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2021013109A (es) Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue.
HK1243414A1 (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
MY191539A (en) Streptococcal vaccine
MX2017002803A (es) Coronavirus bovino atenuado y vacunas relacionadas.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2017015279A (es) Exasomas y su uso como vacunas.
WO2015159155A3 (en) Novel ademetionine formulations
PL2996675T3 (pl) Formulacja farmaceutyczna, sposób wytwarzania formulacji farmaceutycznej i roztwór do infuzji oraz ich zastosowanie jako wyrobu medycznego i/lub leku
WO2016077580A3 (en) Compositions and methods for treating melanoma
WO2016091890A3 (en) Meningitidis vaccines comprising subtilinases
IL259451B (en) A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens
ZA201700164B (en) Influenza virus vaccines and uses thereof
MX2018013358A (es) Vacunas para el virus del papiloma humano y metodos para su uso.